Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity
Intrapleural immunotherapy, radiotherapy and chemotherapy were employed in that sequence in 22 patients with Stage III non-oat cell bronchogenic carcinoma confined to the thorax. Seven patients received intrapleural BCG in a pilot study and 15 were randomized between intrapleural BCG and intrapleural saline. Isoniazid was begun on day 14 and irradiation (3000 rad in 10 fractions) to the primary lesion, mediastinum and ipsilateral supraclavicular nodes was started on day 21. One to two weeks following irradiation, CAMP chemotherapy was initiated (Cyclophosphamide 300 mg/M/sup 2/ iv, d. 1,8; Adriamycin 20 mg/M/sup 2/ iv, d. 1,8; Methotrexate 15 mg/M/sup 2/ iv, d. 1,8 and Procarbazine 100 mg/M/sup 2/ p.o., d. 1 to 10). Chemotherapy was given for a total of six months. Two patients expired prior to radiotherapy (1 tumor progression, 1 myocardial infarction) and 2 patients were lost to follow-up. Nausea, vomiting, alopecia and fatigue were universal side effects of the chemotherapy. Esophagitis occurred in 9 patients, 7 prior to and 2 after initiation of Adriamycin. In only one case did Adriamycin exacerbate a previous radiation esophagitis. No patient developed clinical radiation pneumonitis, although all had eventual radiation fibrosis. Congestive heart failure occurred in 1 patient with known valvular heart disease and responded to diuretics. Three patients developed localized herpes zoster infections. One patient developed radiation myelitis one year after initiating therapy and six months after completing all chemotherapy. The major side effect was leukopenia with relative platelet sparing. Although significant morbidity was encountered in this primarily older patient population (mean age 64.8 years) recall reactions involving irradiated intrathoracic structures were not a significant clinical problem.
- Research Organization:
- Albany Medical Coll., NY
- OSTI ID:
- 5339501
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 5:8; Conference: Conference on combined modalities: chemotherapy/radiotherapy. Part 1, Hilton Head Island, SC, USA, 15 Nov 1978
- Country of Publication:
- United States
- Language:
- English
Similar Records
Adriamycin and enhanced radiation reaction in normal esophagus and skin
Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: a prospective study. [/sup 60/Co]
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
BIOLOGICAL RADIATION EFFECTS
CHEMOTHERAPY
SIDE EFFECTS
DOXORUBICIN
TOXICITY
ENDOXAN
METHOTREXATE
PATIENTS
RADIOTHERAPY
RESPIRATORY SYSTEM DISEASES
ANEMIAS
BIOLOGICAL EFFECTS
FRACTIONATED IRRADIATION
LEUKOPENIA
NAUSEA
VOMITING
ALKYLATING AGENTS
ANTIBIOTICS
ANTIMETABOLITES
ANTIMITOTIC DRUGS
DISEASES
DRUGS
HEMIC DISEASES
IRRADIATION
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
PATHOLOGICAL CHANGES
RADIATION EFFECTS
RADIOLOGY
SYMPTOMS
THERAPY
560151* - Radiation Effects on Animals- Man
550603 - Medicine- External Radiation in Therapy- (1980-)